Perfluorocarbon Nanoparticle-Mediated Platelet Inhibition Promotes Intratumoral Infiltration of T Cells and Boosts Immunotherapy.

Zaigang Zhou,Baoli Zhang,Wenjing Zai,Lin Kang,Ahu Yuan,Yiqiao Hu,Jinhui Wu

DOI: https://doi.org/10.1073/pnas.1901987116

2019-01-01

Abstract:Significance Trafficking of T cells to tumors is critical for the success of immunotherapy. The success against solid cancers is not as effective as desired owing to limited efficacy in delivering a higher frequency of T cells to the tumor microenvironment. At this time, no useful methods are available to enhance T-cell infiltration in tumors in a short time. New methods that could enhance T-cell trafficking in tumors are urgently in need. Up to now, the role of platelets in limiting T-cell infiltration in tumors is a neglected phenomenon. In our study, for the first time, we proved that perfluorocarbon nanoparticles could promote intratumoral infiltration of T cells via platelet inhibition, resulting in enhanced anti–PD-L1 immunotherapy. Cancer immunotherapy can stimulate and enhance the ability of the immune system to recognize, arrest, and eliminate tumor cells. Immune checkpoint therapies (e.g., PD-1/PD-L1) have shown an unprecedented and durable clinical response rate in patients among various cancer types. However, a large fraction of patients still does not respond to these checkpoint inhibitors. The main cause of this phenomenon is the limited T-cell infiltration in tumors. Therefore, additional strategies to enhance T-cell trafficking into tumors are urgently needed to improve patients’ immune responses. In this study, we screened an array of perfluorocarbon compounds, reporting that albumin-based perfluorotributylamine nanoparticles (PFTBA@Alb) can effectively increase the permeability of tumor blood vessels, and no distinct side effects were found on normal blood vessels. After i.v. administration of PFTBA@Alb, the number of tumor-infiltrating CD8+ and CD4+ T cells showed an obvious rising trend. More important, a striking tumor inhibition rate, reaching nearly 90%, was observed when combining PFTBA@Alb with anti–PD-L1 antibody. These findings suggest that PFTBA@Alb can be regarded as an enhancer for anti–PD-L1 immunotherapy.